Abstract
Background: “Rhupus” is a rare rheumatologic disease defined as the overlap between Rheumatoid Arthritis and Systemic Lupus erythematosus. In this group of patients severe neurologic manifestations are unusual and difficult to diagnose in the clinical practice, with few cases reported in the literature.
Case presentation: A 64-year-old Latin man presented with weight loss, dysphagia and impaired gait. After excluding solid neoplasia, electromyography and nerve conduction studies revealed mononeuritis multiplex in advanced stage. He fulfilled criteria for Rhupus as the etiology and had a satisfactory response to treatment with steroids and a rehabilitation programme at 6 month follow up.
Conclusion: Peripheral nervous system compromise must be recognized as a manifestation of autoimmune disease in order to make a timely diagnosis and treatment.
Antonini L, Le Mauff B, Marcelli C, Aruba A, De Boysson H. Rhupus: a systematic literature review. Autoimmun Rev. 2020;19(9):102612. https://doi.org/10.1016/j.autrev.2020
Simon JA, Granados J, Cabiedes J, Ruiz J, Acolcer J. Clinical and immunogenetics characterization of Mexican patients with “Rhupus”. Lupus. 2002;11(5):287-92. https://doi.org/10.1191/0961203302lu189oa
Bortoluzzi A, Silvagni E, Furini F, Piga M, Govoni M. Peripheral nervous system involvement in systemic lupus erythematosus: a review of the evidence. Clin Exp Rheumatol. 2019;37(1):146-55.
Tanemoto M, Hisahara S, Hirose B, Ikeda K, Matsushita T, Suzuki S, et al. Severe mononeuritis multiplex due to rheumatoid vasculitis in rheumatoid arthritis in sustained clinical remission for decades. Intern Med. 2020;59(5):705-10. https://doi.org/10.2169/internalmedicine.3866-19
Aringer M, Costenbader KH, Daikh DI, Brinks R, Mosca M, Ramsey-Goldman R et al. 2019 EULAR/ACR classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12. https://doi.org/10.1136/annrheumdis-2018-214819
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81. https://doi.org/10.1002/art.27584
Lockshin MD, Levine AB, Erkan D. Patients with overlap autoimmune disease differ from those with “pure” disease. Lupus Sci Med. 2015;2(1):e000084. https://doi.org/10.1136/lupus-2015-000084
Solis U, Martínez JP, Prada DM, Gómez JA, Valdés JL, Molinero C. Rhupus syndrome: a rare combination. Rev Colomb Reumatol. 2917;24(4):237-41. https://doi.org/10.1016/j.rcreue.2017.05.004
Bartels CM, Bridges AJ. Rheumatoid vasculitis: vanishing menace or target for new treatments? Curr Rheum Rep. 2010;12(6):414-9. https://doi.org/10.1007/s11926-010-0130-1
McShane CM, Murray LJ, Landgren O, O’Rorke MA, Korde N, Kunzmann AT, et al. Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23(2):332-42. https://doi.org/10.1158/1055-9965.EPI-13-0695
Shimanovsky A, Alvarez Argote J, Murali S, Dasanu C. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016;6:12-8. https://doi.org/10.1016/j.bbacli.2016.05.004

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Alvaro Guillermo Zarama Valenzuela, Diana Paola Valencia Camacho